Cargando…

The diagnostic effectiveness of serum sialic acid predicts both qualitative and quantitative prostate cancer in patients with prostate-specific antigen between 4 and 20 ng/mL

INTRODUCTION: This study aimed to evaluate the predictive value of the serum biochemical index, including alkaline phosphatase (AKP), lactate dehydrogenase (LDH), α-L-fucosidase (AFU), serum sialic acid (SA), and fibrinogen (FIB), for prostate cancer (PCa) and clinically significant prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Jingtao, Yan, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461389/ https://www.ncbi.nlm.nih.gov/pubmed/37645415 http://dx.doi.org/10.3389/fendo.2023.1188944

Ejemplares similares

Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL
por: Ahn, Jae Hyun, et al.
Publicado: (2014)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
por: Iwamoto, Hiroaki, et al.
Publicado: (2019)

Diagnostic Efficiency of Pan-Immune-Inflammation Value to Predict Prostate Cancer in Patients with Prostate-Specific Antigen between 4 and 20 ng/mL
por: Zhu, Meikai, et al.
Publicado: (2023)

Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis
por: Kan, Hung-Cheng, et al.
Publicado: (2017)

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
por: Lee, Seung Hwan, et al.
Publicado: (2011)

Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml
por: Wang, Xuan, et al.
Publicado: (2016)

The Diagnostic Values of Pretreatment Serum Inflammation Markers and Lipoprotein in Men With Total Prostate-Specific Antigen Between 4 and 10 ng/ml
por: Li, Guangping, et al.
Publicado: (2020)

Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
por: Koo, Jin Mo, et al.
Publicado: (2010)

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL
por: Chen, Na, et al.
Publicado: (2017)

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(−1)
por: Chen, Rui, et al.
Publicado: (2015)

Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL)
por: Chung, Jae Hoon, et al.
Publicado: (2020)

Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10–20 ng/mL and normal digital rectal examination
por: Chiu, Peter Ka-Fung, et al.
Publicado: (2016)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Diagnostic Accuracy of Prebiopsy Ga-68 PSMA PET/CT in Detecting Primary Prostate Carcinomas with Prostate-Specific Antigen <50 ng/ml
por: Chandra, Piyush, et al.
Publicado: (2020)

Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml(−1) to 10 ng ml(−1)
por: Zhang, Chi-Chen, et al.
Publicado: (2022)

Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL?
por: Koc, Gokhan, et al.
Publicado: (2017)

Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma
por: Gu, Yulin, et al.
Publicado: (2019)

A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL
por: Miyoshi, Yasuhide, et al.
Publicado: (2022)

Comparison of Multiparametric Magnetic Resonance Imaging and Gallium-68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Detecting Carcinoma Prostate in Patients with Serum Prostate-Specific Antigen between 4 and 20 ng/ml
por: Soni, Brijesh Kumar, et al.
Publicado: (2021)

Predictive Factors for Prostate Cancer in Biopsy of Patients with Prostate-Specific Antigen Levels Equal to or Less Than 4 ng/ml
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy
por: Wu, Qiang, et al.
Publicado: (2021)

Prostate-specific antigen 10–20 ng/mL: A predictor of degree of upgrading to ≥8 among patients with biopsy Gleason score 6
por: Santok, Glen Denmer R., et al.
Publicado: (2017)

Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less
por: LIU, Xin, et al.
Publicado: (2015)

Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis
por: Huang, Yan, et al.
Publicado: (2018)

Correlation between Gleason score distribution and Prostate Health Index in patients with prostate-specific antigen values of 2.5–10 ng/mL
por: Choi, Joongwon, et al.
Publicado: (2020)

Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis
por: Jin, Yan, et al.
Publicado: (2022)

Comparison of prostate cancer detection rates of various prostate biopsy methods for patients with prostate-specific antigen levels of <10.0 ng/mL in real-world practice
por: Oh, Kyung Tak, et al.
Publicado: (2020)

Is targeted biopsy really needed when performing systematic prostate biopsy to raise the detection rate for prostate cancer in patients with prostate-specific antigen ≤10 ng/mL?
por: Park, Jee Soo, et al.
Publicado: (2019)

Association of Nadir Prostate-specific Antigen >0.5 ng/mL after Dose-escalated External Beam Radiation with Prostate Cancer-specific Endpoints
por: Sheth, Niki, et al.
Publicado: (2018)

A pilot study on the use of serum glyoxalase as a supplemental biomarker to predict malignant cases of the prostate in the PSA range of 4-20 ng/ml
por: Chavan, Sushant V., et al.
Publicado: (2011)

Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China
por: Dai, Zhihong, et al.
Publicado: (2021)

Impact of Real-Time Elastography versus Systematic Prostate Biopsy Method on Cancer Detection Rate in Men with a Serum Prostate-Specific Antigen between 2.5 and 10 ng/mL
por: Taverna, Gianluigi, et al.
Publicado: (2013)

Prospective performance of the Prostate Health Index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4–10 ng/mL and negative digital rectal examination
por: Sriplakich, Supon, et al.
Publicado: (2018)

Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10 ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease?
por: Taverna, Gianluigi, et al.
Publicado: (2012)

Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL
por: Lu, Yangbai, et al.
Publicado: (2022)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
por: Fiamegos, Alexandros, et al.
Publicado: (2016)

Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL
por: Kashiwabara, Takeshi, et al.
Publicado: (2018)

Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0–10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium
por: Chen, Rui, et al.
Publicado: (2015)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS
por: Adegun, Patrick Temi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j7b12qre0ohgk6vci2dstr7q6d